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Background: Chronic under perfusion of the skeletal muscle tissues is a contributor to a 29 
decrease in exercise capacity in patients with heart failure reduced ejection fraction (HFrEF).  30 
This under perfusion is due, at least in part, to impaired nitric oxide (NO) bioavailability. 31 
Oral inorganic nitrate supplementation increases NO bioavailability and may be used to 32 
improve exercise capacity, vascular function and mitochondrial respiration.  33 
Methods: Sixteen patients with HFrEF (15 men, 63 ± 4 y, BMI: 31.8 ± 2.1 kg∙m-2) 34 
participated in a randomised, double-blind, crossover design study. Following consumption 35 
of either  nitrate rich beetroot juice (16 mmol nitrate/day), or a nitrate-depleted placebo for 36 
five days participants completed separate visits for assessment of exercise capacity, 37 
endothelial function and muscle mitochondrial respiration. Participants then had a two week 38 
washout prior to completion of the same protocol with the other intervention. Statistical 39 
significance was set a priori at p<0.05 and between treatment differences were analysed via 40 
paired- t-test analysis.  41 
Results: Following nitrate supplementation both plasma nitrate and nitrite increased (933%, 42 
p<0.001 and 94%, p< 0.05, respectively). No differences were observed for VO2peak (nitrate 43 
18.5 ± 5.7ml∙kg-1∙min-1, placebo: 19.3 ± 1.4ml∙kg-1∙min-1; p=0.13) or time to exhaustion 44 
(nitrate: 1165 ± 92sec, placebo: 1207 ± 96sec, p=0.16) following supplementation. There 45 
were no differences between interventions for measures of vascular function, mitochondrial 46 
respiratory function or protein expression (all p>0.05).  47 
Conclusions: Inorganic nitrate supplementation did not improve exercise capacity and 48 
skeletal muscle mitochondrial respiratory function in HFrEF. Future studies should explore 49 




NEW AND NOTEWORTHY 52 
This is the largest study to date to examine the effects of inorganic nitrate supplementation in 53 
patients with HFrEF and the first to include measures of vascular function and mitochondrial 54 
respiration. While daily supplementation increased plasma nitrite, our data indicates that 55 
supplementation with inorganic nitrate as a standalone treatment is ineffective at improving 56 
exercise capacity, vascular function or mitochondrial respiration in patients with HFrEF. 57 
 58 









































Patients with chronic heart failure (CHF) are characterised by reduced aerobic capacity 98 
(VO2peak) and early fatigue (6). Improving VO2peak is an important clinical goal in CHF as it is 99 
correlated with reduced mortality rate and increased quality of life (13, 29).  100 
 101 
It is well accepted that impairments in peripheral tissues have a significant contribution to the 102 
reduced exercise capacity in patients with CHF (3). Nitric oxide (NO), a free radical released 103 
by the endothelium in response to shear stress, is a key regulator of peripheral tissue blood 104 
flow and has been linked to vascular function, mitochondrial function and tissue perfusion 105 
(24, 25). Reductions in NO bioavailability and impaired mitochondrial function play a critical 106 
role in limiting exercise capacity in patients with CHF and are associated with the 107 
development and progression of the syndrome (8, 25). As such, it is important to uncover 108 
whether increasing NO bioavailability through exogenous NO precursors can improve 109 
peripheral function and exercise capacity in patients with CHF. 110 
 111 
Inorganic nitrate supplementation increases NO bioavailability, via the nitrate-nitrite-NO 112 
reduction pathway (32). Nitrate supplementation has been shown to modify exercise capacity 113 
in patients with peripheral arterial disease and in some forms of CHF (16, 17, 34, 36). While 114 
previous studies demonstrate the efficacy of oral nitrate supplementation to increase exercise 115 
capacity in patients with preserved ejection fraction (HFpEF), the potential of the 116 
intervention in those with a reduced ejection fraction (HFrEF) is poorly understood due to 117 
limited few studies (4, 10, 17, 41). Additionally, no previous nitrate supplementation studies 118 
in CHF populations have explored the potential effects on vascular function and 119 
mitochondrial respiratory function. As both have been previously identified as mediators of 120 
health and exercise capacity, exploring the efficacy of nitrate for improving these outcomes 121 
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could be of significant clinical value. To date, oral inorganic nitrate studies in HFrEF have 122 
had small sample sizes and heterogeneous ejection fraction (EF) inclusion criteria.   123 
 124 
Therefore, the primary aim of this study was to test the hypothesis that chronic oral inorganic 125 
nitrate supplementation will improve VO2peak during treadmill exercise in patients with 126 
HFrEF. Secondary aims were to determine the effects on vascular function and skeletal 127 
muscle mitochondrial respiratory function in this population. 128 
 129 
METHODOLOGY 130 
The full protocol for this clinical trial was previously published (35). The study was a 131 
randomized, placebo-controlled, double blind crossover study. It was approved by the 132 
Melbourne Health and by Victoria University Human Ethics Committees and has been 133 
registered in the Australian New Zealand Clinical Trials Registry 134 
[ACTRN12615000906550]. 135 
 136 
The study design is illustrated in Figure 1. In brief, following a screening visit, participants 137 
were randomised to consume either nitrate-rich beetroot juice (210 ml, 16 mmol nitrate) or a 138 
nitrate-depleted placebo for five days (210 ml, <0.1 mmol nitrate) (James White Drinks, 139 
Ipswich, UK). Following this five-day loading, the participants continued daily dosing until 140 
the completion of the three testing visits (average days dosing prior to CPX=7, vascular= 10, 141 
biopsy= 15). The total days of supplementation and testing order were matched for each 142 





Recruitment and eligibility 146 
Participants were identified through medical chart reviews and interested individuals were 147 
provided a detailed description of the nature of the study and, if interested, were invited to 148 
sign an informed consent and complete a screening cardiopulmonary exercise test that also 149 
served as a familiarisation visit. Participants were screened either over the phone or in person 150 
to ensure they met all inclusion criteria. The key criteria were for participants to have an EF 151 
<40%, be on stable medications (for 3 months), and to have no existing injuries. While 152 
individuals with comorbidities were invited to participate, CHF had to be considered their 153 
primary condition (see Figure 2). In total, 882 medical charts were reviewed, nineteen 154 
participants were recruited and sixteen individuals (62.6 ± 3.6 years) with diagnosed HFrEF 155 
(EF 30.4 ± 1.8 %) completed the study. 156 
 157 
Supplementation 158 
Participants consumed a total of 210 ml (16 mmol nitrate) per day. They were asked to 159 
consume one 70 ml bottle with each meal. However, on testing days they were requested to 160 
consume the morning dose exactly 2.5 hours prior to the appointment time (15, 32).  161 
Compliance to supplementation and conversion of nitrate to nitrite was confirmed by a blood 162 
draw on each of the two interventional CPX testing visits.  For the duration of the trial, all 163 
participants were asked to refrain from the use of any type of mouthwash due to 164 
demonstrated reductions in conversion of nitrate to nitrite via oral bacteria (33). They were 165 
also asked to maintain their normal dietary and exercise patterns for the duration of the study. 166 
While diet was not specifically monitored throughout the study, participants were given 167 




Aerobic capacity assessment  170 
The CPX tests utilised a two-step treadmill protocol whereby all participants first completed 171 
six minutes of low-intensity walking at 1.4 km/hour at a 4% grade. The protocol then 172 
increased in speed or incline (in an individualised manner, with intensities replicated at 173 
subsequent visits) every two minutes. All tests were continued until the participant reached 174 
volitional exhaustion. The total time to exhaustion was recorded as the total exercise 175 
duration. Expired respiratory gases were collected breath-by-breath via a facemask attached 176 
to a gas analyser (Medgraphics, cardio2 and CPX/D System – Utilising Breezeex Software, 177 
142090-001, Revia, Minnesota, USA) and heart rate (HR) was monitored continuously via a 178 
12-lead ECG (Mortara, X-Scribe II, Milwaukee, WI, USA). The gas exchange threshold was 179 
calculated via the V-slope method (2). VO2peak was recorded as the average VO2 over the 180 
final 30 seconds of exercise. Tissue oxygenation was captured noninvasively using a near-181 
infrared spectrometry (NIRS, PortaMon, Artinis Medical Systems B.V., The Netherlands) 182 
device positioned on the medial side of the gastrocnemius muscle of the participant. Prior to 183 
placement of the device, a skinfold assessment was performed. Individuals with a reading 184 
>200mm did not have the NIRS device placed as the adipose tissue thickness in these 185 
individuals would interfere with the NIRS interpretation. 186 
 187 
Plasma nitrate and nitrite concentrations 188 
Venous blood draws were taken at each of the testing CPX visits to confirm supplementation 189 
adherence and conversion of nitrate to nitrite. Following five minutes of seated rest, a venous 190 
blood sample was drawn from the antecubital vein, immediately transferred into five 1 ml 191 
microtubes containing 5 µL heparin (1 to 1000 µ/ml) and centrifuged at 3°C for 3 minutes at 192 
5,000 g). The plasma was removed, snap frozen in liquid nitrogen and transferred to a -80°C 193 
freezer for storage until subsequent analysis. Analysis of plasma nitrite and nitrate 194 
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concentrations was performed utilising Ozone-based chemiluminescence using a Sievers 195 
NOA model 280i (GE Analytical Instruments) in conjunction with a custom-designed 196 
reaction chamber (28). 197 
 198 
Vascular function 199 
Participants were asked to hold all morning medications until vascular post-testing. 200 
Following 10 minutes of supine rest, endothelial function was assessed via brachial artery 201 
flow mediated dilation (FMD) using a high-resolution ultrasound (Terason, LifeHealthcare, 202 
New South Wales, Australia) with R wave trigger (35). Ten-second video clips were captured 203 
in duplicate at baseline and during forearm occlusion and a continuous two-minute video was 204 
captured after the occlusion cuff release (reactive hyperaemia). Peak change following 205 
reactive hyperaemia was calculated as the percentage change in brachial artery diameter from 206 
baseline to immediately following peak hyperaemia. 207 
 208 
For all BP measurements, the non-invasive SphygomoCor® (AtCor Medical, Sydney, NSW, 209 
Australia) diagnostic system was utilised (12). A SphygomoCor® brachial blood pressure 210 
(BP) cuff was fitted on the upper arm. The system recorded pulsations at the brachial artery 211 
and produced (via a generalised transfer function) aortic pressure waveforms and predicted 212 
central systolic BP, diastolic BP, mean arterial pressure, pulse pressure, augmentation index 213 
and aortic pressure.  Two measurements were captured, with the lower of the two readings 214 
recorded. If the two blood pressure readings were >6 mmHg apart, a third measure was 215 
recorded to ensure a true resting value and the average of the two lowest BP were recorded. 216 
 217 
Muscle biopsies 218 
Muscle biopsy samples were collected from the vastus lateralis, using a Bergström biopsy 219 
needle with manual suction, as previously described (20). Biopsies were performed in the 220 
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morning with the participant in a fasted state, with the exception of the beetroot juice 221 
supplementation. Individuals who were taking a prescribed blood thinner (n=4), if approved 222 
by the doctor, were asked to withhold this medication for the 48hours prior to the muscle 223 
biopsy for each intervention arm of the trial. One portion (10-20 mg) was immediately 224 
immersed in a 5 ml tube containing ~3 ml of biopsy preserving solution kept on ice and used 225 
for in-situ measurements of mitochondrial respiratory function, while the other portion was 226 
immediately frozen in liquid nitrogen and stored at -80°C for subsequent analyses. 227 
 228 
Fibre preparation and high-resolution respirometry 229 
Procedures for the following protocol have been previously published (27). Muscle fibres 230 
were separated with forceps and immediately placed in ice-cold preserving solution BioPS.  231 
The plasma membrane was permeabilised by agitation for 30 min at 4°C in BioPS containing 232 
50 μg/ml saponin and subsequently washed in the respiration medium MIR05. Mitochondrial 233 
respiration was measured in duplicate (from 2–4 mg wet weight of muscle fibres) in MiR05 234 
at 37°C, using a high resolution respirometer (Oxygraph-2k, Oroboros, Innsbruck, Austria). 235 
A substrate-uncoupler-inhibitor titration (SUIT) protocol was utilised (27). The SUIT 236 
sequence was as follows:  malate (2 mM) and pyruvate (5 mM) in the absence of adenylates 237 
were added for measurement of leak respiration (CI)L. ADP (5 mM) was added for 238 
measurement of oxidative phosphorylation capacity(CI)P.  Succinate (10 mM) was added for 239 
the measurement of p through complex 1 and 2 combined (CI+II)P. Cytochrome c (10 mM) 240 
was then added to test for outer mitochondrial membrane integrity (an oxygen flux increase 241 
of  <15% from (CI+II)p was considered acceptable). This was followed by a series of 242 
stepwise carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) titrations (0.75–1.5 243 
mM), for measurement of electron transport capacity (E) through CI and CII (CI+II)E. 244 
Rotenone (0.5 mM), an inhibitor of CI, was added to determine E through CII (CII)E. Finally, 245 
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the addition of antimycin A (2.5 mM), an inhibitor of CIII, allowed measurement and 246 
correction of residual oxygen consumption (ROX), indicative of non-mitochondrial oxygen 247 
consumption. Reoxygenation during the protocol was by direct syringe injection of O2 was 248 
necessary to maintain O2 levels between 275 and 450 nmol/ml and to avoid potential oxygen 249 
diffusion limitation. Oxygen concentration (in nanomoles per milliliter) and flux (in 250 
picomoles per second per milligram) were recorded with DatLab software (Oroboros). 251 
Mitochondrial specific respiration (pmol O2∙s-1∙CS-1) was calculated by normalising mass-252 
specific respiration (pmol O2∙s-1∙mg-1) by the citrate synthase activity (mol∙h-1∙kg protein-1). 253 
 254 
Whole-muscle lysates 255 
The protein concentration of muscle sample homogenates was determined in triplicate with a 256 
commercial colorimetric assay (Protein Assay kit-II; Bio-Rad, Gladesville, NSW, Australia), 257 
against bovine serum albumin standards (BSA, A9647; Sigma-Aldrich). 258 
 259 
Western blotting 260 
Protein content of the muscle homogenates were assessed using standard western blot 261 
protocol (23). Equal amounts of total protein were loaded into wells on CriterionTM 4-20% 262 
TGX Stain-FreeTM Precast gels (Bio-Rad) and normalised against mixed homogenate internal 263 
standards as previously described (23). The primary antibodies used were from Cell 264 
Signaling Technology and included AKT (#9272), p-AKT ser473 (#9271), p38MAPK 265 
(#9212), p-p38MAPK Thr180/Tyr182, #9211), mTORC1 (#2983), p-mTORC1 ser2448 266 
(#5586). One antibody from Calbiochem for PGC-1α (#st1202) was also utilized. Following 267 
TBST washes, samples were incubated at room temperature with the appropriate host 268 
species–specific secondary antibody for 60 min, before being exposed to a 269 
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chemiluminescence solution. Images were taken with a ChemiDoc Imaging System fitted 270 
(Bio-Rad). Densitometry was performed with Image Lab 5.0 software (Bio-Rad).  271 
 272 
Citrate synthase activity analysis 273 
Citrate synthase (CS) activity was determined in triplicate on a 96 well microtiter plate by 274 
adding 5 μL of a 6 mg∙ml-1 muscle homogenate (freeze thawed in liquid nitrogen twice), 40 275 
μL of 3mM acetyl CoA, 25 μL of 1mM 5,59-dithiobis (2-nitrobenzoic acid) (DTNB), 165 μL 276 
of 100 mM Tris buffer (pH 8.3, kept at 30 °C). After addition of 15 μL of 10 mM oxaloacetic 277 
acid, the plate was immediately placed in an xMark-Microplate spectrophotometer (Bio-Rad) 278 
at 30°C, and after 30 s of linear agitation, absorbance at 412 nm was recorded every 15 s for 279 
3 min. CS activity is reported as moles per hour per kilogram protein.  280 
 281 
Statistical analysis 282 
Statistical analysis was performed using Statistical Package for the Social Sciences (version 283 
22 (SPSS Inc. Chicago, IL, USA). Between treatment differences were analysed via paired t-284 
tests.  Statistical significance was set a-priori at p< 0.05. Figures were created utilising 285 
GraphPad Prism Version 7.00 for Windows (GraphPad Software, La Jolla, California USA). 286 
Unless otherwise indicated, all results are presented as mean ± standard error of the mean 287 
(SEM).  288 
 289 
Results       290 
Nineteen patients commenced the trial, however, three dropped out prior to completion of 291 
both rounds of testing due to reasons unrelated to the study. Anthropometric and clinical 292 
characteristics of the 16 who completed the study are described in Table 1. There was a 293 
single female participant in the study. Statistical analyses were conducted both including and 294 
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excluding this participant’s data. As the results of this sub analyses did not result in 295 
significantly alter the findings (by either including or excluding this data point), the 296 
participant was included.  297 
 298 
Plasma nitrate/nitrite 299 
Adherence to the supplementation was ~98%, as confirmed by dosing logs and bottle cap 300 
returns. Plasma nitrate and nitrite concentrations increased following supplementation (933%, 301 
p<0.001 and 94%, p< 0.05) respectively, Figure 3A-D. One participant’s plasma nitrite data 302 
was excluded from the analysis due to a concentration 4 standard deviations above the mean. 303 
 304 
Exercise outcomes 305 
There were no differences in VO2peak (Figure 4 A) or TTE (Figure 4 B) between the nitrate 306 
and placebo interventions.  307 
 308 
Similarly, there were no differences between the two treatments in deoxygenated or 309 
oxygenated haemoglobin at rest or at any stage of the exercise testing (Figure 5). Additional 310 
numerical data are displayed for each stage in Supplementary Table 1 311 
(https://figshare.com/s/a3f0d84096353204636a ). 312 
 313 
Vascular function 314 
Twelve participants completed the vascular testing (four could not be analysed due to 315 
insufficient image quality). There were no significant differences between interventions in 316 
the resting brachial BPs (SBP, DBP and MAP) between the placebo and nitrate 317 
interventions (∆= -2, -1, -2 mmHg, all p>0.30). There were also no significant differences in 318 




Finally, there were no differences in resting brachial artery diameters (nitrate 3.92 ± 0.16 mm 321 
and placebo 4.0 ± 0.13 mm, p=0.44) or peak reactive hyperaemic response (nitrate 5.7 ± 1.1 322 
% and placebo 4.1 ± 0.68 %, p=0.06) between interventions. 323 
 324 
Mitochondrial respiratory function  325 
Seven patients completed duplicate skeletal muscle biopsies. Absolute values for both mass 326 
specific (pmol O2.s-1∙1mg-1) and mitochondrial specific (pmol O2 s-1∙CS-1) respiration values 327 
are presented in Supplementary Table 2 https://figshare.com/s/f169ec7501a557dda895. None 328 
of the examined parameters were significantly different between interventions (all p>0.05). 329 
 330 
There were no differences noted in maximal oxidative phosphorylation between the nitrate 331 
and placebo interventions (Figure 6, p>0.05) and no correlations between any of the mass-332 
specific or mitochondrial-specific respiration values and VO2peak (all correlations p>0.1).  333 
 334 
There were no differences between the nitrate and placebo interventions for mTORC1 335 
(Figure 7 A-D) p38MAPK (Figure 7 E; 4 H) Akt (Figure 7 I-L) and PGC-1α (Figure 7 M-N). 336 
 337 
Discussion 338 
We report that in patients with HFrEF, chronic oral inorganic nitrate supplementation had no 339 
significant effect on aerobic exercise capacity, vascular function, peripheral and central blood 340 
pressures or muscle respiration. 341 
 342 
Previous studies in both healthy and clinical cohorts have indicated significant increases in 343 
plasma nitrate and nitrite following supplementation (1, 7, 10, 21). In the present study, there 344 
was a significant increase in plasma nitrate and nitrite following supplementation.  However 345 
in absolute terms, a 342nM increase in plasma nitrite is relatively low compared to previously 346 
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reported levels in HFpEF (795nM) and healthy (580nM) subjects.  This is despite the present 347 
study utilising a higher dose than the majority of previous clinical trials, (1, 5, 7, 10, 17, 18, 348 
30). This suggests a potential poor conversion of nitrate to nitrite in HFrEF. The oral 349 
microbiome has been shown to play a crucial role in the conversion of plasma nitrate to 350 
nitrite, and previous studies have shown that even a single dose of mouthwash can entirely 351 
inhibit the conversion process due to its effect at neutralizing required nitrate reducing 352 
bacteria. While most supplementation studies, including the present one, now restrict 353 
mouthwash use, it is possible that the micriobiome of individuals with HFrEF is distinct and 354 
that there is an innate disruption in the reduction pathway. Future studies should consider 355 
exploring the reduction pathway in HFrEF and HFpEF.  356 
 357 
For the main outcomes of the study, there were no differences between peak or submaximal 358 
aerobic capacities between treatments. These findings are in agreement with a previous study 359 
in HFrEF which reported no improvement in exercise capacity following a smaller (12.9 360 
mmol) chronic dose of inorganic nitrate (10). The present study also showed no differences in 361 
gas exchange threshold or VO2 during recovery. There have been two previous positive 362 
findings for aerobic capacity in the HFrEF patient cohort, however, they employed varying 363 
cutoffs for EF% (including patients with EF >40% in their samples) and one utilized a 364 
recumbent cycle modality which may have increased venous return to the right atrium and 365 
influenced central hemodynamics (4, 17). When these factors are controlled for, it appears 366 
supplementation has no effect on aerobic exercise capacity in HFrEF. 367 
 368 
One of the most reported benefits of nitrate supplementation is a reduction in SBP (14, 32, 369 
37). While previous studies in HFpEF have consistently demonstrated decreases in peripheral 370 
BP following supplementation, the data in HFrEF suggest no beneficial effect to blood 371 
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pressure. To our knowledge, this was the first study to assess vascular function parameters in 372 
HFrEF following nitrate supplementation under controlled conditions including having 373 
participants arrived fasted from food, caffeine and medications. We reported no differences in 374 
peripheral or central measures of BP nor vascular stiffness between nitrate and placebo 375 
interventions. Our results corroborate and expand on the findings of previous smaller trials in 376 
HFrEF showing no effect on BP.  377 
 378 
No previous studies which have utilised nitrate supplementation with patients with CHF have 379 
examined the effects FMD (7, 11, 39, 40). In the present study, the peak percent change in 380 
brachial diameter from baseline following nitrate supplementation was 5.7% compared to 381 
4.2% following placebo.  This response is similar to another nitrate supplementation study in 382 
patients with hypercholesterolemia (nitrate: 6.8%, placebo: 4.9%, p=0.05) (31). FMD is 383 
mediated, at least in part, by NO bioavailability and thus it was postulated that 384 
supplementation targeting an increase in NO would lead to an increase in FMD response, 385 
suggesting improved vascular function (9). While our results suggest that the 386 
supplementation could have some beneficial effect on endothelial function, neither of the 387 
changes were significant, nor did they translate into improvements in other clinical or 388 
functional measures. While improving vascular function remains a critical goal in CHF, 389 
improving FMD through nitrate supplementation may not be the best target for improving 390 
clinical or functional measures in this population. 391 
 392 
While increases in tissue oxygenation have been a demonstrated benefit of nitrate 393 
supplementation in patients with peripheral arterial disease and in HFpEF, this has not been 394 
seen in HFrEF (10, 34, 40). In the current study, we report no effect of supplementation on 395 
tissue oxygenation as measured by NIRS. We also report, for the first time in HFrEF, that 396 
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mitochondrial respiration and mitochondrial-related protein expression following 397 
supplementation did not change. At the onset of this clinical trial, a previous study in humans 398 
had demonstrated that nitrate supplementation could improve mitochondrial efficiency via 399 
increasing the capacity for ATP synthesis (19). However, to date these results have yet to be 400 
replicated with nitrate or nitrite supplementation in mice nor human models (22, 26). Herein 401 
we also confirm no beneficial effect on mitochondrial function. Together these findings 402 
suggest that chronic nitrate supplementation alone may not be a sufficient stimulus to elicit 403 
increases in muscle tissue oxygenation or respiration in HFrEF. It is possible that nitrate 404 
supplementation in HFrEF does not translate to an increase in nitrate/nitrite within the muscle 405 
tissues. Researchers have recently demonstrated that in rodents and healthy humans skeletal 406 
muscle can act as a reservoir for nitrate that is then reduced following intense exercise (38). 407 
This storage mechanism has yet to be demonstrated in the muscle tissue of clinical 408 
populations and should be a focus for future studies. 409 
 410 
The current study has several potential limitations. While the study is the largest to date in 411 
this population, it was still a relatively small sample size. The patient population was also 412 
primarily male (n=15). This was not intentional as recruitment was open to both men and 413 
women, but the lack of women participants does limit the applicability of the findings. In line 414 
with some of previous studies assessing the effects of nitrate supplementation in cohorts of 415 
patients with CHF, recruitment in the present study was inclusive of those individuals with 416 
diagnosed chronic comorbidities (hypertension, diabetes and COPD). Participants with any 417 
comorbidity that was either uncontrolled or that was identified as a primary contributor to 418 
reduced exercise capacity or symptomology, however, were excluded. Additionally, dietary 419 
logs were not a component of this trial. While participants were asked to maintain their 420 
normal dietary habits and were given a list of high nitrate food items to avoid, the diet was 421 
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not specifically controlled for beyond these measures.  Another limitation of the study is that 422 
there was only an assessment for plasma nitrate/nitrite performed during the CPX visit of 423 
each interventional arm. We therefore do not know what the nitrate/nitrite values are for 424 
individual subjects beyond this visit. While a previous dose response study has indicated that 425 
nitrate/nitrite levels are maintained for 15 days with continued supplementation, we did not 426 
measure this directly in the current study (37). Finally, the measures for muscle tissue 427 
oxygenation were performed in the vastus lateralis whereas the NIRS placement was on the 428 
gastrocnemius. The measures being performed in different tissues makes it difficult to draw 429 
comparisons, but there were no changes noted in either measure. 430 
 431 
In conclusion, increasing NO bioavailability in HFrEF via oral inorganic nitrate 432 
supplementation appears to be ineffective at improving aerobic capacity in patients with 433 
stable HFrEF. There were also no noted benefits to either vascular function or muscle tissue 434 
oxygenation/respiration. These findings are in contrast with the mainly positive effects seen 435 
in HFpEF and suggest the potential of a physiological discord between the two HF 436 
classifications. This is supported by previous studies suggesting that individuals with HFpEF 437 
potentially have higher levels of vascular dysfunction, which may suggest a differentiation in 438 
therapeutic target for nitrate/nitrite.  Additionally, the relatively poor conversion rate of 439 
nitrate to nitrite in HFrEF may be a key limitation in the efficacy of oral inorganic nitrate 440 
supplementation treatment approaches.  Future studies should characterize the diversity and 441 
abundance of the oral microbiome in HFrEF to elucidate approaches that could lead to a 442 
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Figure Legends 590 
 591 
Figure 1 Study design 592 
Adapted from Woessner et al. (35) (https://www.researchprotocols.org/2018/4/e86/) under 593 
the terms of Creative Commons Attribution License 4.0. Copyright © Mary N. Woessner, 594 
Itamar Levinger, Christopher Neil, Cassandra Smith, Jason D Allen 595 
 596 
Figure 2 Participant flow diagram 597 




Figure 3 The effect of nitrate supplementation on circulating plasma nitrate and nitrite  600 
Mean plasma nitrate (A) and plasma nitrite (C) following inorganic nitrate (16 mmol/ day for 601 
five days and one acute dose 2.5 hours prior of 6.4 mmol) supplementation. Individual 602 
subject responses for nitrate (B) and nitrite (D). One participant’s nitrite data were excluded 603 
(n=15, 14 men and 1 woman) due to abnormal levels (4SD above the mean). * indicates 604 
p<0.05 level, ** indicates p<0.001.  605 
 606 
 607 
Figure 4 The effect of nitrate supplementation on VO2peak and TTE 608 
VO2peak (A) and TTE (B) during the CPX were not significantly different between the two 609 
interventions. Data reported as mean ± standard error of the mean (SEM). Data are displayed 610 
for n=16 (15 men and 1 woman). Abbreviations: TTE, time to exhaustion, VO2peak, peak 611 
aerobic capacity. No significant differences were noted (all p>0.05). 612 
 613 
 614 
Figure 5 The effect of nitrate supplementation on oxygenated and deoxyengenated 615 
haemoglobin 616 
This figure shows group mean differences for HHb (A) and HbO2 (B) values measured from 617 
the NIRS device. The data from the two interventions were matched at specific time points 618 
and demonstrate no significant differences between any measured time points for either 619 
variable. The zero point on the x-axis is the start of exercise and the vertical dotted line 620 
represents the transition between the steady state (first 6 minutes) and the incremental steps 621 
of the maximal CPX. To control for the alterations in arterial/venous capacitance during 622 
transition from rest to exercise, each NIRS output was individually examined. As the units in 623 
NIRS are arbitrary, each participant’s baseline value was adjusted to zero point by visually 624 
identifying the muscle pump action after onset of exercise and selecting the first point after. 625 
This value in AU was then zeroed out and every subsequent point was adjusted by this 626 
baseline value. Data are displayed for n=12 men. Four participants were excluded from final 627 
NIRS analysis due to poor signal quality. . p>0.05 at all timepoints. 628 
 629 
Figure 6 Mass specific and mitochondrial-specific respiratory function for maximal 630 
oxidative phosphorylation capacity  631 
Data are displayed as mean ± SEM of complex I and complex II (CI +CII)P oxidative phosphorylation 632 
capacity in both the placebo and nitrate conditions. Data are displayed for n=7 men. p>0.05 for all 633 




Figure 7 Effect of nitrate supplementation on mitochondrial protein concentration  636 
Relative protein concentrations of total and phosphorylated mTORC1, p38MAPK and Akt 637 
and calculated phosphorylated to total ratios. Data is displayed as mean ± SEM and 638 
individual values for all proteins. Data are displayed for n=7 men. p>0.05 for all analyses. 639 
Abbreviations: Akt, protein kinase, MAPK, mitogen-activated protein kinase, mTORC1, 640 










Table 1 Participant Demographics 
Variable Value 
Age, mean ± SEM, y 62.6 ± 3.6 
Height, mean ± SEM, cm 167.9 ± 3.9 
Mass, mean ± SEM, kg 87.7 ± 4.0 
 BMI ± SEM  kg∙m-2 31.8 ± 2.1 
Male, n (%) 15 (93.75) 
EF ± SEM , % 30.4 ± 1.8 
Aetiology, n (%) 
  Ischaemic  9 (56.25) 
  Non-Ischaemic Dilated Cardiomyopathy 6 (37.5) 
  Idiopathic Heart Disease 1 (6.25) 
New York Heart Association Class, n (%) 
  Class I 3 (18.75) 
  Class II 10 (62.5) 
  Class III 3 (18.75) 
Weber Class Distribution, n (%) 
  Class A (VO2>20ml∙kg-1∙min-1) 5 (31.25) 
  Class B (VO2 16-20 ml∙kg-1∙min-1) 6 (37.5) 
  Class C (VO2 10-15.9 ml∙kg-1∙min-1) 4 (25) 
  Class D (VO2 <10 ml∙kg-1∙min-1) 1 (6.25) 
Comorbidities, n (%) 
  Diabetic  6 (37.5) 
  COPD 2 (12.5) 
  HTN 7 (43.75) 
  Current Smoker 3 (18.75) 
  Obese 9 (56.25) 
Drug therapy, n (%) 
  Metformin 4 (25) 
  β-Blockers 15 (93.75) 
  ACE Inhibitor/ARBs 11 (68.75) 
  Statin 7 (43.75) 
  Aspirin 9 (56.25) 
  Diuretics 12 (75) 
 
Abbreviations: BMI- body mass index, COPD- chronic obstructive pulmonary disease, EF- 
ejection fraction, HTN- hypertension, SEM- standard error of the mean. 
 
 
Table 2 Effects of nitrate supplementation on aortic pressure and stiffness  
  
        
Measurement Placebo   Nitrate Significance  
AorSBP 
(mmHg) 122 ± 4 121 ± 4 0.64 
AorDBP 
(mmHg) 82 ± 3 80 ± 3 0.51 
AorMAP 
(mmHg) 96 ± 4 95 ± 3 0.71 
AorPP (mmHg) 40 ± 2 40 ± 2 0.77 
AorAP (mmHg) 15 ± 2 14 ± 2 0.74 
AorAIX (%) 32 ± 3 35 ± 3 0.3 
 
Abbreviations: Aor, aortic, SBP, systolic blood pressure, DBP, diastolic blood pressure, 
MAP, mean arterial blood pressure, PP, pulse pressure, AP, augmentation pressure, AIX, 
augmentation index. 
 
